GenSight Biologics S.A.
SIGHT.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -94.6% | -48.1% | 19.2% | – |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 100% | 100% | 100% | 113.2% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -13,979.2% | -826.4% | -424.9% | -793.4% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -14,514.6% | -908.9% | -338.4% | -983.3% |
| EPS Diluted | -0.054 | -0.075 | -0.071 | -0.28 |
| % Growth | 27.5% | -5.9% | 74.8% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | €0 | €0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |